Search research articles
Contact Us
Filters
Showing results (51-60 of 58) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 58 results.
Cancer Research
|
November 21, 1998
The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene
K T Hogan, D P Eisinger, S B Cupp, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 14, 1998
Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development
D J Kittlesen, L W Thompson, P H Gulden, et al.
International Journal of Cancer
|
May 8, 2001
Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients
G V Yamshchikov, D L Barnd, S Eastham, et al.
The Journal of Experimental Medicine
|
February 1, 1996
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
J C Skipper, R C Hendrickson, P H Gulden, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 7, 1998
Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha
T Tüting, C C Wilson, D M Martin, et al.
Melanoma Research
|
March 20, 2001
Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study
S P Harlow, D N Krag, T Ashikaga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2001
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes
C L Slingluff, G Yamshchikov, P Neese, et al.
Cancer Immunology, Immunotherapy : CII
|
February 7, 2001
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens
C L Slingluff, T A Colella, L Thompson, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 58) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 58 results.
Cancer Research
|
November 21, 1998
The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene
K T Hogan, D P Eisinger, S B Cupp, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 14, 1998
Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development
D J Kittlesen, L W Thompson, P H Gulden, et al.
International Journal of Cancer
|
May 8, 2001
Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients
G V Yamshchikov, D L Barnd, S Eastham, et al.
The Journal of Experimental Medicine
|
February 1, 1996
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
J C Skipper, R C Hendrickson, P H Gulden, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 7, 1998
Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha
T Tüting, C C Wilson, D M Martin, et al.
Melanoma Research
|
March 20, 2001
Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study
S P Harlow, D N Krag, T Ashikaga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2001
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes
C L Slingluff, G Yamshchikov, P Neese, et al.
Cancer Immunology, Immunotherapy : CII
|
February 7, 2001
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens
C L Slingluff, T A Colella, L Thompson, et al.
Page
of 6